Bluetongue vaccines in Europe

Journal title

Polish Journal of Veterinary Sciences




No 2


Divisions of PAS

Nauki Biologiczne i Rolnicze


Polish Academy of Sciences Committee of Veterinary Sciences ; University of Warmia and Mazury in Olsztyn




DOI: 10.2478/v10181-011-0048-1 ; ISSN 1505-1773


Polish Journal of Veterinary Sciences; 2011; No 2


C Batten (2008), A European field strains of bluetongue virus derived from two parental vaccine strains by genome segment reassortment, Virus Res, 137, 56, ; J Boone (2007), Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep, Vaccine, 25, 672, ; M Boyce (2007), Recovery of infectious bluetongue virus from RNA, J Virol, 81, 2179, ; K De Clercq (2009), Emergence of bluetongue serotypes in Europe, part 2: the occurrence of a BTV-11 strain in Belgium, Transbound Emerg Dis, 56, 355, ; M Enserink (2008), Animal disease. Exotic disease of farm animal tests Europe's response, Science, 319, 710, ; European Commission (<b>2008</b>) Commission Decision 2008/655/EC of 24 July 2008 approving the emergency vaccination plans against bluetongue of certain Member States and fixing the level of Community's financial contribution for 2007 and 2008. No. C(2008) 3757) internet page <a target="_blank" href='http://ec.europa.en/food/animal/diseases/control-measures/docs/decision2008-288-bt-vaccination.pdf'>http://ec.europa.en/food/animal/diseases/control-measures/docs/decision2008-288-bt-vaccination.pdf</a> ; J Gethmann (2009), Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions, Vaccine, 27, 4118, ; B Gorman (1990), The bluetongue viruses, Curr Top Microbiol Immunol, 162, 1. ; C Hamers (2009a), Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep, Vaccine, 27, 2789, ; C Hamers (2009b), Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle, Vet Rec, 165, 369, ; M Hofmann (2008), Genetic characterization of toggenburg orbivirus, a new bluetongue virus from goats, Switzerland, Emerg Infect Dis, 14, 1855, ; Z Lobato (1997), Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens, Vet Immunol Immunopathol, 59, 293, ; N MacLachlan (1994), The pathogenesis and immunology of bluetongue virus infection of ruminants, Comp Immunol Microbiol Infect Dis, 17, 197, ; N MacLachlan (2009), The pathology and pathogenesis of bluetongue, J Comp Pathol, 141, 1, ; S Maan (2011), Novel bluetongue virus serotype from Kuwait, Emerg Infect Dis, 17, 886. ; P Mellor (2002), Bluetongue virus in the Mediterranean Basin 1998-2001, Vet J, 164, 20, ; F Menzies (2008), Evidence for transplacental and contact transmission of bluetongue virus in cattle, Vet Rec, 163, 203, ; R Noad (2009), Bluetongue vaccines, Vaccine, 27, 86, ; C Patta (2004), Bluetongue vaccination in Europe: the Italian experience, Vet Ital, 40, 601. ; A Perrin (2007), Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants, Vaccine, 25, 6774, ; B Rodriquez-Sanchez (2008), Orbiviruses in the Mediterranean basin: updated epidemiological situation of bluetongue and new methods for the detection of BTV serotype 4, Transbound Emerg Dis, 55, 205, ; P Roy (1990), Recombinant virus vaccine for bluetongue disease in sheep, J Virol, 64, 1998. ; P Roy (1992), Protective efficacy of virus-like particles for bluetongue disease, Vaccine, 10, 28, ; P Roy (2009), Prospects for improved bluetongue vaccines, Nat Rev Microbiol, 7, 120, ; G Savini (2004), Virological and serological response of sheep following field vaccination with bivalent modified-live vaccine against bluetongue virus serotypes 2 and 9, Vet Ital, 40, 631. ; G Savini (2004a), Neutralizing antibody response in cattle after vaccination with monovalent modified-live vaccine against bluetongue virus serotype 2, Vet Ital, 40, 668. ; G Savini (2004b), Monovalent modified-live vaccine against bluetongue virus serotype 2: immunity studies in cows, Vet Ital, 40, 664. ; G Savini (2007), An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy, Vet Microbiol, 124, 140, ; G Savini (2008), Vaccines against bluetongue in Europe, Comp Immunol Microbiol Infect Dis, 31, 101, ; G Savini (2009), Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle, Vet Microbiol, 133, 1, ; M Schleiss (2006), Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine, Vaccine, 24, 6175, ; I Schwartz-Cornil (2008), Bluetongue virus: virology, pathogenesis and immunity, Vet Res, 39, 46, ; R Wackerlin (2010), Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle, Vaccine, 28, 4348, ; T Walton (2003), The history of bluetongue and a current global overview, Vet Ital, 40, 31. ; A Wilson (2009), Bluetongue in Europe: past, present and future, Philos Trans R Soc Lond B Biol Sci, 364, 2669,